Simufilam found safe in review of ongoing Alzheimer's clinical trials
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue without modification.| Alzheimer's News Today
Otsuka is stopping the development of AVP-786, its experimental therapy to treat agitation in people with Alzheimer’s disease.| Alzheimer's News Today
Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for Alzheimer’s dementia.| Alzheimer's News Today
Fujirebio asked the FDA to approve its blood test for Alzheimer's disease, which would be the first commercially available test of its kind.| Alzheimer's News Today
BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities.| Alzheimer's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Alzheimer's News Today
The U.S. FDA has approved monthly maintenance dosing for Leqembi, a treatment for early Alzheimer’s disease.| Alzheimer's News Today
The use of Montelukast oral film was shown to improve cognition in patients with mild to moderate Alzheimer's in a Phase 2 clinical trial.| Alzheimer's News Today
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild Alzheimer’s disease.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year.| Alzheimer's News Today
